Interim-analysis of the COSA (COVID-19 patients treated with the Seraph® 100 Microbind® Affinity filter) registry.

Julius J SchmidtDan Nicolae BorchinaMariet van T KloosterKhalida Bulhan-SokiReuben OkiomaLarissa HerbstDiego Sandoval RodríguezVedran PremužićStefan BüttnerBirgit BaderWojciech SerednickiEwa ZasadaMichael SchmitzRalf A QuabachMaria HrinchevaThomas FühnerJan T Kielstein

Published in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2021)

The treatment of COVID-19 patients with Seraph®100 is well tolerated and the circuit failure rate was lower than previously reported for KRT in COVID-19 patients. Mortality corelated with late initiation of Seraph treatment after ICU admission and bacterial superinfection infection. Compared to predicted mortality according to 4C-Score and SOFA Score, mortality of Seraph®100 treated patients reported in the registry was lower.

Keyphrases

sars cov
coronavirus disease
cardiovascular events
end stage renal disease
emergency department
newly diagnosed
risk factors
intensive care unit
chronic kidney disease
ejection fraction
cardiovascular disease
type diabetes
combination therapy
replacement therapy
mechanical ventilation